Mapi Pharma to Showcase Depot Technologies and Partnership Opportunities at Evercore HealthCONx 2024

Actively involved in the development of long-acting injectable therapeutics for unmet medical needs, Mapi Pharma Ltd., a biopharmaceutical company in the clinical stage, is to present at the 7th Annual Evercore HealthCONx Conference held in Coral Gables, Florida from December 3-5, 2024. The company’s senior management headed by the Chairman and the CEO Mr. Ehud Marom is availably for face-to-face meetings to discuss new collaboration prospects with the purpose of furthering the company’s exclusive Depot technologies in multiple therapeutic categories.

As a company specializing in products for a number of diseases including multiple sclerosis, diabetes, schizophrenia, Huntington’s disease, tardive dyskinesia, and hormone receptor-positive early breast cancer, Mapi is well-equipped to assist biopharma brands looking for lifecycle management partners. The company possesses well-developed and dedicated R&D, Depot labs and GMP manufacturing facility that help it to develop, manufacture and commercialize long-acting injectable products proficiently.

“Our special Depot technologies like Deutetrabenazine Depot and Anastrazole Depot are distinct advantages for enhancing the treatment results,” stated Marom. M api has focused on co-development models in which it takes charge of formulation, preclinical and clinical dealing, and regulatory filings; partners assume the development cost and control the commercialization. These relationships are structured to provide performance based payment and royalties to support sustainable growth and product development.”